Alpharma Inc. is a global specialty pharmaceutical company with leadership positions in products for humans and animals. Uniquely positioned to expand internationally, Alpharma is presently active in more than 60 countries. Alpharma is among the world’s leading producers of several important pharmaceutical-grade bulk antibiotics, has a growing branded business and is internationally recognized as a leading provider of pharmaceutical products for poultry, swine and cattle.

Alnylam Pharmaceuticals, a leader in RNAi therapeutics, is a biopharmaceutical company developing novel therapeutics based on a breakthrough in biology known as RNA interference, or RNAi; a discovery that enables the creation of a broad new class of human therapeutics. Using RNAi, Alnylam has built a product platform to develop a deep pipeline of drug products to treat a wide array of important diseases.

Allos Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing innovative small molecule therapeutics for the treatment of cancer. Its lead product candidate, EFAPROXYN, is a synthetic small molecule designed to sensitize hypoxic, or oxygen-deprived, tumor tissue during radiation therapy. EFAPROXYN is currently being evaluated as an adjunct to whole brain radiation therapy in a pivotal Phase 3 trial in women with brain metastases originating from breast cancer.

Allion Healthcare, Inc. is a specialty drug distributor focusing on patients with HIV and AIDS. The company fulfills prescriptions for necessary medications at its seven distribution centers and delivers them to patients, doctors’ offices, and clinics nationwide. Allion also offers special software and packaging of drug orders — pre-filled pill boxes that are intended to help patients stick with their medication regimens.

Advanced Life Sciences, Inc, is a biopharmaceutical company focused on the discovery, development and commercialization of novel drugs in the areas of infectious disease, inflammation and oncology. Using its internal discovery capabilities and the network of pharmaceutical and academic partners, it has assembled a promising pipeline of clinical and preclinical product candidates for the treatment of respiratory tract infections, human immunodeficiency virus, acute respiratory distress syndrome and cancer.

Æterna Zentaris Inc. is a growing global biopharmaceutical company focused on oncology and endocrine therapy with proven expertise in drug discovery, development and commercialization. The company operates in three segments: Biopharmaceutical, Active Ingredients & Specialty Chemicals (AISC), and Health & Nutrition (H&N).

Adolor Corporation is a biopharmaceutical company specializing in the discovery, development and commercialization of novel prescription pain management products. It has more than 150 employees working in areas including discovery research, drug development, clinical research, manufacturing, business development and marketing. Adolor was founded to capitalize on emerging proprietary development in cloned opioid receptors and continues today as a leader in the discovery and development of novel opioid receptor-targeted therapeutics.

Adams Respiratory Therapeutics is a specialty pharmaceutical company focused on the late-stage development, commercialization, and marketing of over-the-counter, or OTC, and prescription pharmaceuticals for the treatment of respiratory disorders. Adams currently markets 2 OTC products under its Mucinex brand and expects to launch 4 additional products that are already approved by the US Food and Drug Administration.

Acusphere, Inc. is a specialty pharmaceutical company that develops new drugs and improved formulations of existing drugs using its proprietary porous microparticle technology. It is focused on developing proprietary drugs that can offer significant benefits such as improved safety and efficacy, increased patient compliance, greater ease of use, expanded indications or reduced cost.

Aceto Corporation is a global leader in the distribution and marketing of Pharmaceutical and Specialty Chemicals used principally in the agricultural, color, pharmaceutical, surface coating/ink and general chemical industries.

ZymoGenetics is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic proteins for the prevention or treatment of human diseases. The Company is developing a diverse pipeline of potential proprietary product candidates that are moving into and through clinical development. These span a wide array of clinical opportunities that include bleeding, autoimmune diseases and cancer. ZymoGenetics intends to commercialize these product candidates through internal development, collaborations with partners, and out-licensing of patents from its extensive patent portfolio.

Ivax Corporation is a multinational company engaged in the research, development, manufacturing and marketing of branded and generic pharmaceuticals and veterinary products in the U.S. and internationally. It is headquartered in Miami, Florida, has direct operations in 39 countries, and markets products in more than 80 countries around the globe.

Sepracor Inc. is a research-based pharmaceutical company dedicated to treating and preventing human disease through the discovery, development, and commercialization of innovative pharmaceutical products that are directed toward serving unmet medical needs.

Shire Pharmaceuticals Group is a global specialty pharmaceutical company with revenues for the full year 2004 of $1,363.2 million and an operating income of $446.4 million. It has a global sales and marketing infrastructure with a broad portfolio of products and its own direct marketing capability in the US, Canada, UK, Republic of Ireland, France, Germany, Italy and Spain.

Barr Pharmaceuticals, Inc. develops, manufactures and markets generic and proprietary pharmaceuticals. The Company’s product portfolio includes more than 100 generic and proprietary pharmaceutical products in core therapeutic categories including female healthcare (including oral contraceptive and hormone therapy products), oncology, cardiovascular, anti-infective and psychotherapeutic pharmaceuticals.

Lundbeck, founded in 1915, is the only fully integrated pharmaceutical company focusing entirely on finding new and effective therapies for central nervous system (CNS) disorders. This strategic focus allows Lundbeck to establish strong links with academics, clinicians and patients with interests in CNS disorders.

Founded in 1717 and headquartered in Osaka, Japan, Ono Pharmaceutical specializes in its own research and development. Its primary research fields are Prostaglandins, Enzyme Inhibition, Neuroscience, and Intracellular Transmission.

Allergan, Inc., with headquarters in Irvine, California, is a global specialty pharmaceutical company that develops and commercializes innovative products for the eye care, neuromodulator, skin care and other specialty markets. In addition to its discovery-to-development research programs, Allergan has global marketing and sales capabilities in over 100 countries that deliver value to its customers, satisfy unmet medical needs and improve people’s lives. Driven by technology and innovation, Allergan addresses the needs of consumers across the world with over 5,000 employees worldwide, 4 world-class Research and Development facilities and 3 state-of-the-art manufacturing plants.

Suzuken is a pharmaceuticals wholesaler and medical equipment supplier. The company — the largest wholesaler of health care supplies in Japan — has a network of customers that includes hospitals and health practitioners throughout the country. Suzuken makes such products as electrocardiographs and other medical equipment, as well as over-the-counter, prescription, and veterinary pharmaceuticals, diagnostic tools, monitors, and home health care products. Patient data and inventory management services are also available.

Daiichi Pharmaceutical Corporation (”Daiichi”) is a wholly owned subsidiary of Daiichi Pharmaceutical Co. Ltd., in Tokyo, which was founded in 1915 as Japan’s first research based pharmaceutical company. Daiichi Pharmaceutical Co., Ltd. has established its first subsidiary in the U.S. - Daiichi Pharmaceutical Corporation. The vision in the U.S. is to make Daiichi a preeminent clinical research and sales & marketing driven pharmaceutical company.

Altana Pharma is a research-based company with dynamic growth. It employs some 8,200 people group-wide at locations in Europe, North and Latin America, South Africa, Asia and Australia. It researches, produces and markets medications in its core business of prescription medicines. It also manufactures and markets diagnostic products for imaging technologies and self-medication products which are available without prescription.

Since its foundation in 1912, Taisho Pharmaceutical has sought to fulfill this wish by developing a variety of medications, and resolutely facing new challenges. One aspect of these efforts has been solid support for self-medication, the idea by which individuals assess the state of their health based on their own experience, treating minor ailments with over-the-counter medications. Taisho has focused on becoming a leading company of such self-medication products.

Fujisawa Pharmaceutical produces and markets pharmaceuticals, medical equipment and supplies, home care business, chemicals and animal health products. The company is one of Japan’s largest drug makers, with its main strength in antibiotics. About 35 percent of sales come from overseas, much of which is from sales of its immunosuppressive agent Prograf.

Forest Laboratories, Inc. and its subsidiaries, develop, manufacture and sell ethical drug products, which require a physician’s prescription, as well as non-prescription pharmaceutical products sold over-the-counter (OTC). The Company’s products in United States consist of branded-ethical drug specialties marketed directly or detailed to physicians by the Company’s Forest Pharmaceuticals, Forest Therapeutics, Forest Healthcare, Forest Ethicare and Forest Specialty Sales forces. It promotes in the United States those of its branded products, which has potential for growth and concentrates on group of physicians, who are high-prescribers of its products, such as Namenda, Forest’s N-Methyl-D-Aspartate (NMDA) antagonist for the treatment of moderate to severe Alzheimer’s disease; Lexapro, selective serotonin reuptake inhibitor (SSRI) for the treatment of major depression, and Benicar, an angiotensin receptor blocker for the treatment of hypertension, which Forest co-promotes with Sankyo.

Eisai Inc. is a U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd. Established in 1995, Eisai Inc. began marketing its first product in the United States in 1997 and has rapidly grown to become an integrated pharmaceutical business. Headquartered in Teaneck, New Jersey, it is dedicated to a tradition of genuine concern for people and is driven by the desire to meet the diverse health care needs of patients and their families and caregivers. It is an agile, entrepreneurial organization managed by experienced leadership, backed by the strength, stability and historical successes of Eisai Co., Ltd., which has a strong and lasting commitment to the U.S. market.

Schering-Plough develops and markets prescription and OTC drugs, animal health products, and personal care products. Although the company is best known for its allergy medications Clarinex and Nasonex, the company specializes in anti-infectives (particularly for hepatitis) and cancer drugs. The drugmaker co-promotes erectile dysfunction pill Levitra in the US with GlaxoSmithKline. Schering-Plough’s OTC offerings include allergy medications Claritin, Afrin nasal sprays, the Dr. Scholl’s line of foot care products, and sun care lines Coppertone and Bain de Soleil.

Celesio is the absolute European leader in terms of the distribution of pharmaceutical products (to pharmacies and the hospital sector), backed up by indisputable expertise in logistics, in a profession where pharmacists may expect deliveries up to five time a day.Thus Celesio is working in 11 European countries and is particularly active in Great Britain, France, Germany and Austria. Not content with the packaging, transport and delivery of products, it also has its own chain of pharmacies (Lloyd’s, the British leader, Norsk Medicinal in Norway) among others. Its efficiency confirmed, Celesio is today venturing into B2B e-business.

Sankyo is Japan’s second-largest pharmaceutical company (behind Takeda Pharmaceutical Company). The company’s research and development efforts are concentrated on cancer, diabetes, obesity, cardiovascular disease, rheumatism, and allergy-related conditions. The company’s main products include cholesterol fighter Mevalotin and blood pressure medications Calblock and Acecol. Sankyo develops its drugs through an extensive independent network of laboratories in Europe, South America, and the US. In addition to prescription pharmaceuticals, the company makes OTC medications, veterinary drugs, food ingredients, and agricultural chemicals. Sankyo has agreed to buy Daiichi Pharmaceutical for $7.7 billion.

Yamanouchi Pharmaceutical’s principal activity is the manufacture and sale of a diverse line of ethical and over the counter drugs. Pharmaceuticals including circulatory & respiratory agents, digestive agents and hormone agents; food & flowers including fruits, cakes, chocolates, roses, gardening goods, 14%; nutritional food & personal care products including make-up products, dental care products, house cleaning products and body care products, 7% and other including real estate, insurance agents, nominal.

Teva Pharmaceutical Industries Limited (Teva) is a global pharmaceutical company producing drugs in all major treatment categories. Teva supplies generic drugs, as well as branded products for specific niche categories, such as Copaxone for multiple sclerosis. The Company’s active pharmaceutical ingredients (API) business supplies third-party manufacturers, as well as meets its own production requirements. Teva’s operations are conducted directly and through subsidiaries in Israel, Europe, North America and several other jurisdictions.

McKesson is the largest pharmaceuticals distributor in the US. The company operates in three segments, the largest of which is its pharmaceutical distribution business, which delivers pharmaceuticals, health and beauty care products, medical supplies, and equipment throughout the country from its 30 distribution centers serving all 50 states. McKesson’s Medical-Surgical unit distributes surgical and medical supplies and equipment, and its Provider Technologies segment offers software and services for supply chain management, clinical and financial operations, and pharmacy and health care management.

As a successful pharmaceutical company, Schering Group is investing in the future of medicine. It develops drugs of high medical value so as to continuously improve the quality of life.It makes the most of knowledge. Using interdisciplinary networks it builds bridges to academic researchers around the world, as well as to highly specialized biotech pioneers and partners in the pharmaceutical industry. It combines its own longstanding medical and pharmaceutical expertise with the latest discoveries from genomic research. Throughout, its research focuses on a meaningful combination of early diagnosis, prevention, treatment and therapy control.

Novo Nordisk is one of the world’s leading producers of insulin. In addition, Novo Nordisk offers a line of diabetes education and training materials and services to doctors and patients under the name NovoCare. It also is involved in biopharmaceuticals, which include hemostasis management (for bleeding problems and hemophilia), growth hormone therapy, and hormone replacement therapy. Products include Activelle (hormone replacement), NovoSeven (hemostasis management), and Norditropin SimpleXx (liquid growth hormone).Through its Novo A/S subsidiary, the Novo Nordisk Foundation owns 27% of the shares and controls about 70% of the voting power in Novo Nordisk.

AmerisourceBergen Corporation is a pharmaceutical services company in the United States, which serves both pharmaceutical manufacturers and healthcare providers in the pharmaceutical supply channel. The Company provides drug distribution and related services designed to reduce costs and improve patient outcomes. The Company distributes a line of brand name and generic pharmaceuticals, over-the-counter (OTC) healthcare products and home healthcare supplies and equipment to a wide variety of healthcare providers located throughout the United States, including acute care hospitals and health systems, independent and chain retail pharmacies, mail-order facilities, physicians, clinics and other alternate site facilities, as well as skilled nursing and assisted living centers.

The sanofi-aventis Group is the world’s 3rd largest pharmaceutical company, ranking number 1 in Europe. Backed by a world-class R&D organization, sanofi-aventis is developing leading positions in seven major therapeutic areas: cardiovascular disease, thrombosis, oncology, diabetes, central nervous system, internal medicine, and vaccines. The sanofi-aventis Group is listed in Paris and New York.

Wyeth is a global leader in pharmaceuticals, consumer health care products, and animal health care products. It improves the lives of millions of people around the world with its outstanding products. And other innovative medicines are on the way. With research and development (R&D) programs focused on small molecules, vaccines, and biotechnology, Wyeth is exploring more than 60 new therapies for medical conditions such as diabetes, breast cancer, multiple sclerosis, HIV, Alzheimers disease, and schizophrenia.

Bristol-Myers Squibb is a global pharmaceutical and related health care products company whose mission is to extend and enhance human life. Bristol-Myers Squibb’s 43,000 employees are dedicated to discovering, developing and providing innovative medicines that address significant medical needs of patients worldwide.

Abbott is building a global portfolio around two key groups: pharmaceuticals and medical products. The Pharmaceutical Products Group strives to consistently discover, develop and market breakthrough drugs that improve patient health, especially in areas of unmet medical need. The group’s primary focus is on translating innovative science into effective medicine and spans several areas, including the Pharmaceutical Products Division, the Nutritionals Division and Abbott International, as well as TAP Pharmaceuticals Inc., Abbott’s joint venture with Takeda Chemical Industries, Ltd.

AstraZeneca is one of the world’s leading pharmaceutical companies. It provides innovative, effective medicines designed to fight disease in important areas of medical need: cancer, cardiovascular, gastrointestinal, infection, neuroscience and respiratory.